These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 15023777)

  • 1. The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies.
    Spuls PI; Witkamp L; Bossuyt PM; Bos JD
    Arch Dermatol; 2004 Mar; 140(3):338-44; discussion 344. PubMed ID: 15023777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study.
    Katz KA; Karlawish JH; Chiang DS; Bognet RA; Propert KJ; Margolis DJ
    J Am Acad Dermatol; 2006 Nov; 55(5):814-22. PubMed ID: 17052487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combination Acitretin and Pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial.
    Mittal R; Malhotra S; Pandhi P; Kaur I; Dogra S
    Arch Dermatol; 2009 Apr; 145(4):387-93. PubMed ID: 19380660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
    Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
    J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
    Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
    J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
    Tzellos T; Kyrgidis A; Zouboulis CC
    J Eur Acad Dermatol Venereol; 2013 May; 27(5):622-7. PubMed ID: 22404103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study.
    Kunynetz R; Carey W; Thomas R; Toth D; Trafford T; Vender R
    Eur J Dermatol; 2011; 21(1):89-94. PubMed ID: 21227890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course of guttate psoriasis: long-term follow-up study.
    Ko HC; Jwa SW; Song M; Kim MB; Kwon KS
    J Dermatol; 2010 Oct; 37(10):894-9. PubMed ID: 20860740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's in placebos: who knows? Analysis of randomized, controlled trials.
    Golomb BA; Erickson LC; Koperski S; Sack D; Enkin M; Howick J
    Ann Intern Med; 2010 Oct; 153(8):532-5. PubMed ID: 20956710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Most randomized controlled trials for psoriasis used placebo comparators despite the availability of effective treatments.
    Afach S; Evrenoglou T; Oubaya N; Le Cleach L; Sbidian E
    J Clin Epidemiol; 2021 May; 133():72-79. PubMed ID: 33482295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative evaluation of the antipsoriatic effect of L-dopa versus placebo in psoriasis.
    Savery F; Karassik S; Gast J
    Curr Ther Res Clin Exp; 1976 Aug; 20(2):130-3. PubMed ID: 182438
    [No Abstract]   [Full Text] [Related]  

  • 20. Topical treatments for chronic plaque psoriasis.
    Bailey J; Whitehair B
    Am Fam Physician; 2010 Mar; 81(5):596. PubMed ID: 20187595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.